Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Gene-Edited Cell Therapies: CMC Challenges and Considerations - WHITEPAPER

ArticleImage

Download the exclusive whitepaper

Gene-edited cell therapies showed potential as a treatment for many diseases, especially for blood-based cancer patients who do not respond to any other treatment. And presently, CAR T cells are increasingly being reprogrammed to express small molecules and drugs that can serve as an addition to existing therapies.

This whitepaper reviews the current challenges in manufacturing gene-edited cell therapies and steps to approach them, including:

  • Manufacturing challenges and protocols for gene-edited cell therapies

  • Considerations for allogeneic products, including CAR & T cell products

  • Current industry developments

  • Best practice strategies in maintaining safety/efficacy

  • Opportunities for automation/technological innovation


To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.